Successful Retreatment of Chronic Hepatitis C Virus Genotype 1A Infection With Glecaprevir/Pibrentasvir in a Pediatric Patient With Developmental Disorder
Year: 2026
Type: article
Study design: Case Report
Abstract: BACKGROUND/AIM: Although direct-acting antiviral (DAA) therapy is now available for pediatric patients with chronic hepatitis C virus (HCV) infection, the challenges associated with its use are similar to those observed in adults. In pediatric patients with chronic hepatitis C virus genotype 1A infection, the granular formulation of glecaprevir/pibrentasvir (GLE/PIB) can make oral administration difficult. CASE REPORT: We report a case of infection in a child with developmental disorder who achieved sustained virologic response after retreatment with a 12-week course of GLE/PIB, following initial treatment failure with GLE/PIB. However, through mother-pharmacy department collaboration, treatment efficacy was achieved by extending the GLE/PIB treatment period in our case, despite initial treatment failure and recurrence. CONCLUSION: Although rare, this single case suggests that prolonged GLE/PIB therapy may be effective following failure with 8-week GLE/PIB therapy.
Source: In Vivo
Authors: TORU ISHIKAWA, KOYATA FUJII, SAEKA SAKAKIBARA, AOI ODAIRA, MITSURU SUSA, TAKATOSHI UCHITSUBO, OKUBO SOICHIRO
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7131836995
FWCI:
Cites:
Cited by:
Related to: